| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1991.9.4.565 |
| P698 | PubMed publication ID | 2066753 |
| P2093 | author name string | S A Weitzman | |
| K Kim | |||
| R L Comis | |||
| M J O'Connell | |||
| R B Mann | |||
| F J Cummings | |||
| R S Neiman | |||
| M M Oken | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase II clinical trial | Q42824440 |
| P304 | page(s) | 565-571 | |
| P577 | publication date | 1991-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease | |
| P478 | volume | 9 |
| Q45239470 | An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma |
| Q40958067 | Bone marrow transplantation in low-grade non-Hodgkin's lymphoma |
| Q34677742 | Cutaneous T-cell lymphoma/leukemia |
| Q36470196 | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management |
| Q48034709 | Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. |
| Q38286313 | Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma |
| Q34155353 | Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease |
| Q33811537 | Emerging new therapies for cutaneous T-cell lymphoma |
| Q52166245 | In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. |
| Q34040863 | Inroads in the therapy of indolent lymphomas: exploiting biological insights |
| Q26774768 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas |
| Q73468261 | Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma |
| Q36430721 | Pentostatin and purine analogs for indolent lymphoid malignancies |
| Q44373542 | Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group |
| Q40385554 | Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders |
| Q35714769 | Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia |
| Q44723870 | Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series |
| Q40479351 | Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias |
| Q41230175 | Purine analogues in the management of lymphoproliferative diseases |
| Q40677466 | Purine metabolism of lymphocytes. Targets for chemotherapy drug development. |
| Q30244553 | T-cell lymphomas, a challenging disease: types, treatments, and future. |
Search more.